Technology Platform
TRIM-edicine is dedicated to the discovery and development of novel protein therapeutics for the treatment of unmet medical needs. Our technology platforms include:
- Protein Therapeutics for tissue repair in chronic disease or traumatic injury
- Biologics for regenerative medicine for genetic disorders involving compromised cellular plasticity and repair capacity
- Bioactive peptides for pharmaceutical and cosmeceutical applications
The company is built around a core of protein therapeutic approaches that involve novel proteins with remarkable biological properties. These unique proteins target a variety of cellular pathways that are altered in numerous disease states. Currently, TRIM-edicine is developing the following proteins:
- MG53 – targeting diseases involving chronic and acute tissue damage
- MG29 – targeting diseases related to aging
- ATAP – targeting cancer